Y-Mabs Therapeutics SEC Filings

John LaRocca, SVP, General Counsel & Secretary of Y-mAbs Therapeutics (YMAB), reported transactions tied to the companys merger completed on 09/16/2025. Pursuant to the Merger Agreement, outstanding restricted stock units (RSUs) and stock options were cancelled and converted into cash payments: RSUs (21,500) were settled for cash at $8.60 per share, and outstanding options were converted into cash equal to the excess of $8.60 over the option exercise price where applicable. Options with an exercise price equal to or above $8.60 were cancelled for no consideration. The filing shows zero shares and zero options beneficially owned by the reporting person after the transactions, and that Y-mAbs became an indirect wholly owned subsidiary of the acquiring parent.

Healy James, a Sofinnova-affiliated director of Y-mAbs Therapeutics (YMAB), reported transactions tied to the company's merger. On 09/16/2025 Purchaser completed a tender offer and merged with the issuer, and each outstanding common share was cancelled for $8.60 cash per share. The reporting person disposed of 31,603 shares and 25,080 restricted stock units were converted into cash in connection with the merger. Outstanding stock options were cancelled and converted into cash equal to the excess of $8.60 over each option's exercise price; options with exercise prices at or above $8.60 were cancelled for no consideration.

Y-mAbs Therapeutics filed a series of Form S-8 registration statements registering common stock for employee equity plans. The filings register: 2,799,373 shares for options under the Amended and Restated 2015 Equity Incentive Plan; 2,122,127 shares for the 2018 Equity Incentive Plan; 578,500 shares for options under the 2018 EIP; 700,000 shares for the 2018 Employee Stock Purchase Plan; 8,078,887 shares (3/30/2023); 1,746,884 shares (2/29/2024); and 1,799,532 shares (3/4/2025) under the 2018 EIP.

Y-mAbs Therapeutics filed a post-effective amendment to registration statements on Form S-8 covering multiple employee equity plans. The filing lists prior Form S-8 registrations that reserve specific share amounts: 2,799,373 shares tied to the 2015 plan options and 2018 plan allocations, 2,122,127 shares under the 2018 Equity Incentive Plan, 578,500 shares for outstanding options under the 2018 plan, 700,000 shares for the 2018 Employee Stock Purchase Plan, and additional 2018 EIP authorizations of 8,078,887, 1,746,884 and 1,799,532 shares on later Forms S-8.

Y-mAbs Therapeutics, Inc. filed post-effective amendments to multiple Form S-8 registration statements to register shares for employee equity plans. The filing lists prior Form S-8 registrations: 2,799,373 shares (2019 filing), 8,078,887 shares (2023 filing), 1,746,884 shares (2024 filing) and 1,799,532 shares (2025 filing), each authorized for issuance under the company's 2015 and 2018 equity plans and an employee stock purchase plan.

Y-mAbs Therapeutics announced a merger agreement that converts outstanding equity awards into cash at the Effective Time. The Agreement and Plan of Merger dated August 4, 2025 is referenced and exhibits including the amended certificate and bylaws are filed. All stock options outstanding immediately before the Effective Time are cancelled and converted into a cash payment equal to the number of shares covered multiplied by the excess of the Merger Consideration over the option exercise price; options with an exercise price at or above the Merger Consideration are cancelled for no consideration. Restricted stock units (RSU Awards) convert into cash equal to the shares issuable multiplied by the Merger Consideration, while performance-based RSUs (PSU Awards) convert into cash based on the maximum number of shares issuable multiplied by the Merger Consideration. The filing references the merger agreement and supporting exhibits but does not disclose the numeric Merger Consideration within the provided text.

Y-mAbs Therapeutics, Inc. submitted a Form 25 notification indicating the company’s class of securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies Nasdaq as the exchange and confirms that the Exchange and the Issuer have followed the procedural rules governing removal or voluntary withdrawal under the Securities Exchange Act. The document is a short procedural notice and does not include financial results, reasons for the removal, effective delisting date, or details about alternate trading arrangements.